FOR AUTHORS
Search
Search Results
##search.searchResults.foundPlural##
-
The landscape of rare coagulation factor deficiency management in Italy: a national hemophilia center survey
1155PDF: 163HTML: 61Appendix: 87 -
Anticoagulation in obese patients: challenges and strategies
1915PDF: 291HTML: 244XML: 116 -
Diagnostic and management practices for inherited fibrinogen disorders: a nationwide survey of Italian Hemophilia Treatment Centers
501PDF: 79HTML: 69Supplementary: 35Appendix: 52 -
PO40 | Management of paediatric patients affected by mild factor VII deficiency undergoing surgery B. Borsellino1,2, B. Pollio1, I. Ricca1, R. Albiani1, T. Martini1 | 1Haemophilia Centre, Immune-Haematology and Transfusion Medicine, University Hospital “Città della Salute e della Scienza”, Turin; 2Department of Biomedicine and Prevention, PhD in Immunology, Molecular Medicine and Applied Biotechnology, University of Roma Tor Vergata, Roma, Italy
495PDF: 0 -
PO27 | B-cell lymphoproliferative disorder and acquired coagulopathy: an insidious link C. Caputo, P. Conca, I.L. Calcaterra, E. Cimino, M. Romeo, M. Aversano, E. Franco, C. De Luca, R. Russo, C. Fierarossa, M.N.D. Di Minno, A. Tufano | Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy
528PDF: 0 -
PO12 | IMPACT OF INHERITED THROMBOPHILIA ON CANCER-ASSOCIATED THROMBOSIS: A SYSTEMATIC REVIEW AND META-ANALYSIS E. Campello1, G. Furlan1, A. Boccatonda2, A. Napolitano1, C. Simion1, P. Simioni1 | 1Internal Medicine 1 and Thrombotic and Hemorrhagic Diseases Unit, Department of Medicine, University of Padova, Italy; 2Diagnostic and Therapeutic Interventional Ultrasound Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola-Malpighi, Bologna, Italy
179PDF: 58 -
PO78 | Acquired hemophilia A as a paraneoplastic syndrome: two cases report on a rare coexistence M. Gagliardi, L. Capone, A. Ciampa | Centro Emostasi, AORN Moscati, Avellino, Italy
527PDF: 0 -
PO43 | Extended treatment with reduced dose of direct oral anticoagulants in patients with venous thromboembolism: a retrospective study A. Pannunzio1, E. Valeriani1, I.M. Palumbo1, D. Menichelli1, T. Brogi2, S. Marucci2, D. Pastori2, P. Pignatelli2 | 1Department of General Surgery and Surgical Specialty, Sapienza University of Roma; 2Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Roma, Italy
566PDF: 0 -
The key to fibrinolysis and thrombolysis
1575PDF: 309HTML: 179 -
PO44 | Emicizumab in acquired haemophilia A M. Leotta, A. Strangio, A. Ierardi, S. Prejanò, R C. Santoro | Hemostasis and Thrombosis Unit, Department Hemato-Oncology, Azienda Ospedaliero-Universitaria Renato; Dulbecco, Catanzaro, Italy
530PDF: 0 -
PO21 | Exploring endothelial damage: the interplay between coagulopathy, capillary leak and vasoplegia in sepsis M. Facci1, G. Turcato1, A. Zaboli2, L. Filippi1, P. Ferretto1, M. Maggi1, F. Lucente1, D. Milazzo1, A. Bresolin1, M. Marchetti1 | 1UOC Medicina Generale, Ospedale Alto Vicentino, Santorso, (VI); 2Innovation, Research and Teaching Service “SABES-ASDAA” of Azienda Sanitaria dell’Alto Adige, Italy
468PDF: 0 -
PO77 | The clinical awareness of mixing test interpretation in the era of complex reporting algorithm: do we forget the origins? A. Fassina, L. De Valentin, S. Luzi, R. Turrini, A. Antico, L. Zardo | Laboratorio Analisi Castelfranco Veneto, ULSS Marca Trevigiana, Italy
546PDF: 0 -
PO03 | HEPATIC FIBROSIS–DRIVEN TISSUE FACTOR EXPRESSION BY MALIGNANT CHOLANGIOCYTES IS ASSOCIATED WITH CANCER-ASSOCIATED THROMBOSIS AND POOR SURVIVAL IN INTRAHEPATIC CHOLANGIOCARCINOMA L. Fabris1|2|3, Y. Frión-Herrera1, C. Venturin1|3, M. Cadamuro4, J. Gasparello5, C. M. Radu1|2, M. Fassan1|5, C. Mescoli6, U. Cillo7|8, E. Gringeri7|8, G. Zanus7|9, E. Campello1|2, M. Strazzabosco3, P. Simioni1|2 | 1Department of Medicine, University of Padua; 2Clinical Medicine 1 and Thrombotic and Haemorrhagic Disease Unit, and Haemophilia Center, Padua University-Hospital; 3Department of Internal Medicine, Digestive Disease Section, Liver Center, Yale University, New Haven, CT, USA; 4School of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy; 5Pathology Unit, Ca' Foncello Hospital, ULSS2 Marca Trevigiana, Treviso; 6Pathology Unit, Padua University-Hospital; 7Department of Surgery, Oncology and Gastroenterology, University of Padua; 8Hepatobiliary Surgery and Liver Transplantation Unit, Padua University-Hospital; 9General Surgery Unit, Ca' Foncello Hospital, ULSS2 Marca Trevigiana, Treviso, Italy
218PDF: 45 -
-
OC10 | FROM DESIGN TO CLINICAL PHASE 3 IN ONCOLOGY: CD13-TARGETED TISSUE FACTOR AND TUMOR INFARCTION W.E. Berdel, C. Schwöppe, C. Brand, K. Hessling, A.F. Berdel, T. Kessler, G. Lenz, R.M. Mesters, C. Schliemann | Department of Medicine A, University Hospital, Muenster, Germany
210PDF: 49 -
PO02 | Pregnancy and delivery in women with hemophilia and carriers are still challenging: a ten years analysis from The Italian Association of Hemophilia Centers (AICE) M. Napolitano1, M. Mattana2, C. Cammarata1, M. Leotta3, S. Linari4, M.E. Mancuso5, G. F. Rivolta6, C. Santoro7, L. Valdrè8, R.C. Santoro3, S. Siragusa1 | 1Department of Health Promotion, Mother and Child Care, Internal Medicine and Med, Palermo; University of Palermo, Italy; 2Department of Precision Medicine in Medical, Surgical and Critical Care “Me. Pre. Cc”, University of Palermo; 3Hemostasis and Thrombosis Unit, Azienda Ospedaliera Universitaria Dulbecco, Catanzaro; 4Center for Bleeding Disorders, Careggi University Hospital, Firenze; 5Center for Thrombosis and Hemorrhagic Diseases, IRCCS Humanitas Research Hospital, Rozzano, Milan; 6Regional Reference Center for the Treatment of Congenital Hemorrhagic Diseases, Parma University Hospital, Parma; 7Hematology, University Hospital Policlinico Umberto I, Roma; 8Inherited Bleeding Disorders Unit, IRCCS AOUBO, Bologna, Italy
601PDF: 0 -
PO36 | Venous stenting for symptomatic iliac thrombosis: five-years experience of single center I. Nichele1, G. Marchesini1, L. Boi2, G. Carli1, A. Tosetto1 | 1Hemophilia and Thrombosis Center, Hematology Department, S. Bortolo Hospital, Vicenza; 2Radiology Department, Ospedale Ca’ Foncello, Treviso, Italy
536PDF: 0 -
CO39 | Artificial intelligence in hemophilia management: challenging the need for experts G. Sottilotta1, D. Megalizzi1, F. Luise2 | 1UOSD Microcitemie - Emostasi e Trombosi. Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli, Reggio Calabria; 2Laboratorio Analisi, Grande Ospedale Metropolitano Bianchi-Melacrino-Morelli, Reggio Calabria, Italy
519PDF: 0 -
PO01 | MELANOMA-DERIVED EXTRACELLULAR VESICLES DRIVE VON WILLEBRAND FACTOR–DEPENDENT THROMBOSIS AND METASTASIS Y. Wang1|2, X. Liu1, T. Downar3, A. Topuz4, A. Bauer1, J. Kött1|5, K. Nekipelov6, S. Brenna7, G. Bendas6, B. Puig7, S. Schneider1, D. Fedosov4, C. Gorzelanny1 | 1Department of Dermatology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 2Mildred Scheel Cancer Career Center HaTriCS4, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 3Experimental Dermatology, Medical Faculty Mannheim, Heidelberg University, Mannheim, Germany; 4Institute for Advanced Simulation (IAS-2), Forschungszentrum Jülich, Jülich, Germany; 5Fleur Hiege Center for Skin Cancer Research, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; 6Pharmaceutical Institute, University of Bonn, Bonn, Germany; 7Neurology Department, Experimental Research in Stroke and Inflammation (ERSI), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
233PDF: 53 -
PO38 | Rates of hemorrhagic events and hemodialysis circuit thrombosis in patients with end-stage renal disease on hemodialytic treatment receiving a factor-XI inhibitor: a systematic review and meta-analysis D. Santagata, G. Barbui, M.P. Donadini, A. Squizzato | Department of Medicine and Surgery, Research Center on Thromboembolic Disorders and Antithrombotic Therapies, University of Insubria, Varese and Como, Italy
514PDF: 0 -
PO67 | TARGETED THERAPIES FOR CANCER AND THE RISK OF ARTERIAL AND VENOUS THROMBOEMBOLISM O. Iqbal | Loyola University Stritch School of Medicine, Maywood, IL, USA
225PDF: 78 -
CO19 | Hypercoagulability in wild-type transthyretin amyloidosis: evidence from whole blood thromboelastometry A. Napolitano1, L. Spiezia1, C. Samà1, A. Benetti1, G. Sinigiani2, L. De Michieli2, A. Cipriani2, P. Simioni1 | 1First Chair of Internal Medicine, Department of Medicine, University Hospital of Padua; 2Department of Cardiothoracic and Vascular Sciences & Public Health, University Hospital of Padua, Italy
496PDF: 0 -
PO55 | Evaluation of safety and efficacy of emicizumab prophylaxis in pediatric patients with hemophilia A – a single centre experience M.L. Tramontano, M. Coppola, S. Coppola, M. Schiavulli | UOSD Centro Regionale Pediatrico Malattie della Coagulazione, Santobono Pausilipon Children Hospital, AORN, Napoli, Italy
494PDF: 0 -
PO33 | Whole blood hypercoagulable profiles in patients with rheumatoid arthritis L. Spiezia1, A. Giollo2, C. Samà1, A. Benetti1, L. Di Luozzo2, M. Salvato2, A. Doria2, P. Simioni1 | 1First Chair of Internal Medicine, Thrombotic and Hemorrhagic Diseases Unit, Department of Medicine, University Hospital of Padova; 2Rheumatology Unit, Department of Medicine, University Hospital of Padova, Italy
540PDF: 0 -
PO20 | DYSFUNCTION OF THE ADAMTS-13/VON WILLEBRAND FACTOR AXIS, MEDIATED BY NETOSIS, AS A DRIVER OF PROTHROMBOTIC STATE AND UNFAVORABLE PROGNOSIS IN ONCOGYNECOLOGICAL PATIENTS V. Bitsadze1, E. Beloborodova2, J. Khizroeva1, A. Solopova1, M. Tretyakova1, N. Gashimova1, K. Grigoreva1, A. Tatarintseva1, J. Christophe Gris1|3, I. Elalamy1|4|5, G. Gerotziafas1|4|5, A. Makatsariya1 | 1Department of Obstetrics, Gynecology and Perinatal Medicine, N. F. Filatov Clinical Institute of Children’s Health, I. M. Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia; 2Clinic MEDSI Network of Medical Centers in Moscow, Russia; 3Faculty of Pharmaceutical and Biological Sciences, Montpellier University, France; 4Department Hematology and Thrombosis Center, Medicine Sorbonne University, Paris, France; 5Hospital Tenon, Paris, France
214PDF: 55 -
PO75 | Prophylaxis with RFXIII: a clinical case in a pediatric patient with congenital FXIII deficiency and delayed diagnosis M.L. Tramontano, M. Coppola, S. Coppola, M. Schiavulli | UOSD Centro Regionale Pediatrico Malattie della Coagulazione. Santobono Pausilipon Children Hospital, AORN, Napoli, Italy
534PDF: 0 -
CO15 | Longitudinal coagulation profiling of individuals undergoing gender-affirming hormone therapy: the hyper-gender study A. Napolitano, E. Campello, A. Scala, C. Simion, C. Bulato, S. Gavasso, C. Samà, A. Benetti, S. Toffanin, G. Faggian, R. Scafa, A. Garolla, P. Simioni | First Chair of Internal Medicine, Department of Medicine, University Hospital of Padua; Unit of Andrology and Reproductive Medicine, Department of Medicine, University Hospital of Padua, Italy
568PDF: 0 -
PO49 | Use of emicizumab in two patients with acquired hemophilia A: a new therapeutic approach S. Sorella, J. Micozzi, E. Baldacci, M. Biglietto, R. Mormile, A. Chistolini, R. Ciciani, L. Torrieri, N. Zhdanovskaya, M. Lorenzon, A. Delli Paoli, S. Ligia, C. Santoro | Hematology, Department of Translational and Precision Medicine, Policlinico Umberto I, Sapienza University of Roma, Italy
556PDF: 0 -
PO52 | MECHANISTIC POPULATION PHARMACOKINETIC/PHARMACODYNAMIC AND TIME-TO-EVENT MODELING SUPPORT SUSTAINED FACTOR XI INHIBITION AND SUPERIOR POST-OPERATIVE VENOUS THROMBOEMBOLISM PREVENTION WITH REGN7508CAT O. Milberg1, H. Abdallah1, R.K. Lokken2, R. Dingman1, K.A. Meagher1, P. Banerjee1, M.E. Burczynski1, E. Marin1, A.P. Kithcart1, D.E. Gutstein1 | 1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; 2Allucent, Cary, NC, USA
233PDF: 85 -
PO24 | Emicizumab prophylaxis and bleeding outcomes: a single center clinical experience A. Taglietti1, S. Ligia1, F. Paoletti1, R. Mormile1, E. Baldacci2, A. Chistolini1, C. Santoro1,2 | 1Hematology, Department of Translational and Precision Medicine, Sapienza University of Roma; 2Hematology, Azienda Ospedaliera Universitaria Policlinico Umberto I, Roma, Italy
539PDF: 0 -
PO65 | Utilization of emicizumab in acquired hemophilia A: a case report C. Caputo, P. Conca, I.L. Calcaterra, E. Cimino, M. Romeo, M. Aversano, E. Franco, C. De Luca, G. D’errico, L. Jr Valletta, M. Di Minno, A. Tufano | Department of Clinical Medicine and Surgery, Federico II University, Naples, Italy
520PDF: 0 -
CO09 | Long term effectiveness and safety of direct oral anticoagulants in patients with factor V Leiden and/or prothrombin gene mutation and venous thromboembolism: a single centre, retrospective cohort study I.M. Palumbo1, E. Valeriani1,2, A. Pannunzio1, S. Marucci3, D. Menichelli1, D. Pastori3,4, P. Pignatelli3 | 1Department of General Surgery and Surgical Specialty, Sapienza University of Roma; 2Department of Infectious Disease, Azienda Ospedaliero-Universitaria Policlinico Umberto I, Roma; 3Department of Clinical Internal, Anaesthesiologic and Cardiovascular Sciences, Sapienza University of Roma; 4IRCCS Neuromed, Pozzilli, Italy
671PDF: 0 -
PO51 | MECHANISTIC POPULATION PHARMACOKINETIC/PHARMACODYNAMIC MODELING OF FACTOR XI-TARGETING MONOCLONAL ANTIBODIES SUPPORTS DURABLE ANTICOAGULANT COVERAGE AND TRANSLATIONAL DOSE AND REGIMEN SELECTION O. Milberg1, H. Abdallah1, R.K. Lokken2, R. Dingman1, K.A. Meagher1, M.E. Burczynski1, E. Marin1, A.P. Kithcart1, D. E. Gutstein1 | 1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; 2Allucent, Cary, NC, USA
225PDF: 82 -
PO90 | Acquired hemophilia A with high-titer inhibitor in a patient with cardiovascular and metabolic comorbidities M.G. Mazzone, G. Chiarelli, R. Russo, L. Valletta Jr, G. D’Errico, C. De Luca, P. Rufolo, A. Tufano, E. Cimino, P. Conca, M.N.D. Di Minno | Department of Clinical Medicine and Surgery, Federico II University of Naples, Italy
569PDF: 0 -
OC13 | VON WILLEBRAND FACTOR PREDICTS POOR OUTCOME IN PANCREATIC CANCER AND MEDIATES TUMOR-ENDOTHELIUM INTERACTIONS FACILITATING METASTASIS B. Ünlü1, Z. Zhao1, N. Joshi1, S. De1, A. Chion1, I. Schoen1, J. O’Donnell1, M. Flick2, M. Fishel3|4, J. O’Sullivan1 | 1School of Pharmacy and Biomolecular Sciences, Irish Centre for Vascular Biology, Royal College of Surgeons in Ireland, Dublin, Ireland; 2UNC Blood Research Center, University of North Carolina at Chapel Hill, Chapel Hill, USA; 3IU Simon Comprehensive Cancer Center, Indiana University School of Medicine, Indianapolis, IN, USA; 4Department of Pediatrics, Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN, USA
216PDF: 47 -
PO13 | Monitoring of anti-factor XA activity levels in patients treated with direct oral anticoagulants and concomitant tyrosine kinase inhibitors agents: a monocentric experience E. Santacroce1,2, C. Santoro1, E. Baldacci1, S. Ligia1, R. Mormile1, M. Biglietto1, M. Totaro1, F. R. Mauro1, M. Breccia1, A. Chistolini1 | 1Department of Translational and Precision Medicine, Haematology, Sapienza University of Roma; 2Department of Clinical and Molecular Medicine, Sapienza University of Roma, Italy
553PDF: 0 -
PO23 | Plasmic score applicability for the diagnosis of thrombotic microangiopathy associated with acquired ADAMTS13 deficiency in emergency settings at the hub laboratory of AUSL Romagna: state of the art and future prospects M. Olivieri1, M. Rosetti1, A. Clementoni1, V. Marinucci1, M. Monterosso1, E. Massari1, V. Polli1, M. Zauli1, V. Sambri2 | 1Clinical Pathology Unit; 2Unit of Microbiology, Area Hub Laboratory, Cesena, Italy
557PDF: 0 -
CO37 | Assessment of clotting factor activity and sterility in thawed fresh frozen plasma supplied to helicopter emergency medical services for prehospital transfusion D. Romeo1, M. Marchetti1,2, M. Testa1, A. Motta1, P. Gomez-Rosas1, G. Ravasio1, F. Daminelli3, L. Barcella1, A. Falanga1,2 | 1Immunohematology and Transfusion Medicine Department, Hospital Papa Giovanni XXIII, Bergamo; 2School of Medicine and Surgery, University Milano Bicocca, Milan; 3Anesthesia and Resuscitation Department, Hospital Papa Giovanni XXIII, Bergamo, Italy
581PDF: 0 -
CO02 | Hepatic fibrosis as predictor of cancer-associated thrombosis in patients with intrahepatic cholangiocarcinoma Y. Frion-Herrera1,2, C. Venturin1,3, M. Cadamuro4, J. Gasparello5, C.M. Radu1, M. Fassan5, C. Mescoli6, U. Cillo7, E. Gringeri7, G. Zanus8, L. Fabris1,3, P. Simioni1 | 1Clinical Medicine and Thrombotic and Haemorrhagic Disease Unit, and Haemophilia Center, Padua University-Hospital, Department of Medicine [DIMED], University of Padua, Italy; 2Department of Biology [DiBio], University of Padua, Italy; 3Department of Internal Medicine, Digestive Disease Section, Liver Center, Yale University, New Haven, CT, USA; 4School of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy; 5Department of Pathology Ca’ Foncello Hospital, ULSS2 Marca Trevigiana, Italy; 6Pathology Unit, Padua University-Hospital, Padua, Italy; 7Hepatobiliary Surgery and Liver Transplantation Unit, Padua University-Hospital, Department of Surgery, Oncology and Gastroenterology [DISCOG], University of Padua, Italy; 8General Surgery Unit, Ca’ Foncello Hospital, ULSS2 Marca Trevigiana, Department of Surgery, Oncology and Gastroenterology [DISCOG], University of Padua, Italy
626PDF: 0 -
PO86 | Emicizumab in patients with moderate hemophilia A and severe bleeding phenotype: single-center real-world experience A.L. Faccini, M. Biglietto, S. Sorella, E. Crisanti, M. Antonacci, R. Mormile, R. Ciciani, E. Baldacci, C. Santoro, S. Ligia | Hematology, Department of Translational and Precision Medicine Sapienza University of Roma, Italy
654PDF: 0 -
CO23 | Markers of inflammation and hypofibrinolysis are associated with cognitive dysfunction and motor performances in atrial fibrillation patients on oral anticoagulant therapy: insights from the Strat-AF study F. Alfano1,2, F. Cesari1,2, A.M. Gori1,2, M. Berteotti1,2, E. Salvadori3, B. Giusti1,2, A. Bertelli1,2, F. Fratini4, A. Rogolino1,2, B. Formelli4,5, F. Pescini4,5, E. Fainardi6, E. Barucci4, G. Salti5, A. Cavaliere4, A. Ginestroni6, A. Poggesi4,5, R. Marcucci1,2 | 1Department of Experimental and Clinical Medicine, University of Firenze; 2Center for Atherothrombotic Diseases, Careggi University Hospital, Firenze; 3Department of Biomedical and Clinical Sciences, University of Milan; 4NEUROFARBA Department, Neuroscience Section, University of Firenze; 5Stroke Unit, Careggi University Hospital, Firenze; 6Neuroradiology Unit, Careggi University Hospital, Department of Experimental and Clinical Biomedical Sciences, University of Firenze, Italy
616PDF: 0 -
PO68 | RISK OF VENOUS THROMBOEMBOLISM IN PATIENTS WITH CANCER AND MIGRAINE: A COHORT ANALYSIS AMONG DANISH NATIONAL HEALTH SURVEY PARTICIPANTS O. Rosenkrantz1, P. Szentkúti1, L. Amdisen1, E. Horváth-Puhó1, A.L. Pedersen1, H.E. Bøtker2, H. Elser1|3, J.P. Vandenbroucke1|4|5, H.T. Sørensen1 | 1Department of Clinical Epidemiology and Center for Population Medicine, Aarhus University Hospital and Aarhus University, Denmark; 2Department of Cardiology, Aarhus University Hospital, Department of Clinical Medicine, University of Aarhus, Denmark; 3Department of Neurology, Hospital of the University of Pennsylvania, Philadelphia, PA, USA; 4Department of Clinical Epidemiology, Leiden University Medical School Leiden, The Netherlands; 5School of Hygiene and Tropical Medicine, London, UK
236PDF: 81 -
PO05 | DESIGN, SYNTHESIS, AND BIOLOGICAL EVALUATION OF NOVEL IMATINIB AND NILOTINIB ANALOGUES EXPRESSING ENHANCED ANTIPLATELET AND ANTICANCER ACTIVITIES D. Pantazi1, L. Pechlivani1, A. Kosma1, K. Lalechou1, M.G. Siskos2, D. Alivertis3, A.D. Tselepis1 | 1Atherothrombosis Research Centre, Laboratory of Biochemistry, Department of Chemistry, University of Ioannina, Greece; 2Laboratory of Organic Chemistry, Department of Chemistry, University of Ioannina, Greece; 3Department of Biological Applications and Technology, University of Ioannina, Greece
278PDF: 54 -
PO58 | Gender differences in primary haemostasis A. Becchetti2, M. Brambilla2, M. Conti2, D. Trabattoni2, E. Tremoli3, M. Camera1,2 | 1Department of Pharmaceutical Sciences, Università degli Studi di Milano; 2Centro Cardiologico Monzino IRCCS, Milan; 3Maria Cecilia Hospital, Cotignola (RA), Italy
555PDF: 0 -
CO36 | Inhibitor titer at diagnosis and clinical course in acquired hemophilia A: a single-center experience C. Simion, B. Stocco, E. Dalla Porta, E. Campello, G. Furlan, L. Spiezia, G. Saggiorato, F. Sartorello, E. Zanon, P. Simioni | Department of Medicine – DIMED, University of Padua, Italy
483PDF: 0 -
CS08 | A combination of two rapid immunoassays improves HIT diagnosis G. Ciarrocca Taranta1, A. Rogolino2, A. Bertelli1, A. Sorrentino1, M. Di Gioia2, F. Cesari2, B. Giusti1,2, E. Sticchi1,2, M. Berteotti1,2, A.M. Gori1,2, R. Marcucci1,2 | 1Department of Experimental and Clinical Medicine, University of Firenze; 2Atherothrombotic Disease Unit, Careggi University Hospital, Firenze, Italy
621PDF: 0 -
PO42 | DIFFERENTIAL EXPRESSION OF HEMOSTATIC BIOMARKERS ACROSS CANCER TYPE AND DISEASE STAGE: A PROSPECTIVE ANALYSIS OF 4,292 PATIENTS FROM THE HYPERCAN STUDY P. Gómez-Rosas1|2|, D. Romeo1, S. Bolognini1, C. Ticozzi1, F. Schieppati1, A. D’Alessio4, R. Labianca4, A. Falanga1|5|6, M. Marchetti1|5|6 | 1Hospital Papa Giovanni XXIII, Bergamo, Italy; 2Cardiovascular Research Institute Maastricht (CARIM), Maastricht University, Maastricht, the Netherlands; 3Hospital de Oncologia, Unidad Medica de Alta Especialidad (UMAE), Centro Medico Nacional Siglo XXI, Instituto Mexicano del Seguro Social (IMSS), Mexico City, Mexico; 4Fondazione ARTET Onlus, Bergamo, Italy; 5ERN EuroBloodNet; 6School of Medicine and Surgery, University of Milan Bicocca, Italy; *On Behalf Of The Hypercan Investigators
217PDF: 81 -
PO06 | Extracellular vesicles profiles in patients with porto-sinusoidal vascular disease S. Toffanin1, E. Campello1, A. Zanetto2, C. M. Radu1, E. Pinto2, K. Fernande2, C. Bulato1, B. Serena1, L. Spiezia1, P. Burra2, M. Senzolo2, P. Simioni1 | 1First Chair of Internal Medicine, Department of Medicine, University Hospital of Padua Medical School, Padua; 2Department of Surgery Oncology and Gastroenterology, Gastroenterology and Multivisceral Transplant Unit, University Hospital of Padua, Italy
534PDF: 0 -
Influence of emicizumab on protein C-mediated clotting regulation
2534PDF: 380Supplementary Material: 106 -
OC09 | BLEEDING RISK ASSOCIATED WITH FACTOR XI MONOCLONAL ANTIBODIES IN COMBINATION WITH ASPIRIN IN HEALTHY VOLUNTEERS AND ORTHOPEDIC SURGERY PATIENTS: ANALYSIS FROM RECENT PHASE 1 AND PHASE 2 STUDIES A.P. Kithcart1, M.E. Burczynski1, P. Banerjee1, M. Onisko1, Y. Wang1, K. Mohammadi1, D. Li1, S. Li1, J. Ackroyd2, B.A. Olenchock1, D.E. Gutstein1, J. I. Weitz3 | 1Regeneron Pharmaceuticals, Inc., Tarrytown, NY, USA; 2Clinical Research, Fortrea Clinical Research Unit Ltd, Leeds, UK; 3McMaster University, Hamilton, ON, Canada
192PDF: 62 -
PO45 | Routine prophylaxis with PD-FX concentrate in severe inherited FX deficiency: a case report S. Linari, L. Pieri, M. Attanasio, F. Salvianti, M. Coppo, E. Grisanti, F. Demartis, R. Fjerza, G. Castaman | Centre for Bleeding Disorders and Coagulation, Azienda Ospedaliera Universitaria Careggi, Firenze, Italy
527PDF: 0 -
CO21 | Viscoelastic testing in inherited bleeding disorders: a cross-sectional comparison between viscoelastic coagulation monitoring and rotational thromboelastometry C. Simion, C. Samà, C. Bulato, G. Gottardi, D. Regazzo, E. Campello, P. Simioni | Department of Medicine – DIMED, University of Padua, Italy
537PDF: 0 -
Still unmet problems with low molecular weight heparin prophylaxis of venous thromboembolism. An Italian survey
1357PDF: 251HTML: 138Supplementary: 77 -
PO18 | Does muscle mass matter? Appendicular lean mass as a determinant of anti-XA activity in elderly patientes B.M. Zanforlini1, V. Bernardi1, E. Campello2, E.M. Bicego1, C. Curreri1, A. Vaticano1, C. Sartori1, L. Manfron1, A. Perencin1, P. Rollo1, A. Baruffol1, L. Ruoso1, C. Simion2, C. Bulato2, P. Berto2, P. Simioni2, G. Sergi1 | 1Department of Medicine, Geriatrics Section, University of Padova; 2Haemorrhagic and Thrombotic Diseases Unit, Department of Medicine DIMED, Padova University Hospital, Padova, Italy
521PDF: 0 -
The evolving landscape of gene therapy for congenital severe hemophilia: a 2024 state of the art
1743PDF: 328SUPPLEMENTARY MATERIAL: 173 -
PO04 | FIBRIN CLOT SHIELDS PROMOTE CLONAL SELECTION IN CANCER CELLS: PROCOAGULANT ACTIVITY AND SURVIVAL OF CLOT-EMBEDDED CELLS. A NOVEL TUMOR MICROENVIRONMENT MODEL M.A. Baghdadi1|2, E. Mbemba1, P. Las Casa1, P. Van Dreden1|3, N. Saleem1|4, J. Fareed4, P. Kempaiah4, M. Sabbah1, G. Gerotziafas1|4 | 1Sorbonne University, INSERM UMR_S_938, CRSA, Research Department "Cancer, Vessels, Biology and Therapeutics" (CaVITE), Research Group "Cancer-Angiogenesis-Thrombosis and Haemostasis," Thrombosis Center, University Institute of Cancerology, Saint Antoine University Hospital Assistance Publique Hôpitaux de Paris (AP-HP) Paris, France; 2Research Center, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia; 3Diagnostica Stago, Gennevilliers, France; 4Center of Translational Research and Education, Department of Pathology and Laboratory Medicine, Loyola University Stritch School of Medicine, Maywood, Ill., USA
200PDF: 49 -
PO57 | Direct oral anticoagulant determination in urine samples compared to plasma concentrations in outpatients with atrial fibrillation and obesity A. Pannunzio1, I.M. Palumbo1, D. Menichelli1, V. Cammisotto2, V. Castellani3, E. Baldacci4, R. Mormile4, A. Chistolini4, G. Bernardini5, N. Porcu1, D. Pastori2, J. Harenberg6, F. Violi2, P. Pignatelli2 | 1Department of General Surgery, Surgical Specialties and Organ Transplantation Paride Stefanini, Sapienza University of Roma, Italy; 2Department of Clinical Internal, Anesthesiological and Cardiovascular Sciences, Sapienza University of Roma, Italy; 3Department of Translational and Precision Medicine, Sapienza University of Roma, Italy; 4Department of Hematology, Oncology and Dermatology, Sapienza University of Roma, Italy; 5U.O.S.D. Medicina Rigenerativa DAI, Medicina Diagnostica e Radiologia, Policlinico Umberto 1, Roma, Italy; 6Ruprecht Karls University of Heidelberg, Germany
463PDF: 0 -
CO34 | Evaluation of emicizumab concentration and thrombin generation in a cohort of severe hemophilia A patients with and without inhibitor A. Taglietti1, S. Ligia1, F. Paoletti1, R. Mormile1, E. Baldacci2, A. Chistolini1, C. Santoro1,2 | 1Hematology, Department of Translational and Precision Medicine, Sapienza University of Roma; 2Hematology, Azienda Ospedaliera Universitaria Policlinico Umberto I, Roma, Italy
550PDF: 0 -
CS06 | Patient specific iPSCs-derived sinusoidal endothelial cells for phenotypic correction of haemophilia A A. Benetti1, C.M. Radu1, C. Samà1, M. Trevisan2, C. Simion1, E. Campello1, P. Simioni1 | 1Department of Medicine - DIMED, Padua University Hospital; 2Department of Molecular Medicine, University of Padua, Italy
632PDF: 0 -
PO41 | VENOUS THROMBOEMBOLISM IN PERIPHERAL BLOOD STEM CELL COLLECTION. A SINGLE CENTER EXPERIENCE P. Holly1, J. Hudecek1, J. Chudej1, L. Valekova1, I. Plamenova1, E. Flochova1, R. Simonova1, J. Sokol1, J. Stasko1, M. Pietrzykova1|2, E. Vescecikova2 | 1Department of Hematology and Transfusion Medicine, University Hospital in Martin, Martin, Slovakia; 2National Transfusion Service, Martin, Slovakia
231PDF: 67 -
PO05 | Intensive FVIII replacement in haemophilia patients with hypertrophic synovium: a randomized study I.L. Calcaterra1, E. Baldacci2, R. Marino3, F. Valeri4, R.C. Santoro5, G. Pasta6, C. Martinoli7, M. Di Minno1 | 1Department of Clinical Medicine and Surgery, Federico II University, Naples; 2Haematology, University Hospital Policlinico Umberto I, Roma; 3Haemophilia Center and thrombosis, Policlinico, Bari; 4Regional Centre for Haemorrhagic and Thrombotic Diseases, AOU Città Della Salute e Della Scienza; Turin; 5Centre for Hemorrhagic and Thrombotic Disorders, Pugliese Ciaccio Hospital, Catanzaro; 6Fondazione IRCCS San Matteo Hospital, Pavia; 7Department of Health Science DISSAL, University of Genoa, Unit of Radiology and IRCCS San Martino Hospital, Genoa, Italy
512PDF: 0 -
OC04 | DIRECT ORAL ANTICOAGULANTS PROVIDE EFFECTIVE THROMBOPROPHYLAXIS IN NEWLY DIAGNOSED MYELOMA: REAL WORLD FINDINGS FROM THE ATOMM STUDY T. Bull1, Heamstar Collaborators2, W. Wilson3, E. Ganendra4, M. Thomas5, R. Alikhan6, M. Karanth1, M. Camilleri7 | 1West Suffolk Hospital NHS Foundation Trust, UK; 2Haematology Specialty Training Audit and Research HaemSTAR Network, UK; 3University College London Clinical Trial Centre, UK; 4North West Anglia NHS Foundation Trust, UK; 5University College London Hospitals, UK; 6Cardiff and Vale University Health Board, Wales, UK; 7Cambridge University Hospitals NHS Foundation Trust, UK
285PDF: 64 -
PO64 | MANAGEMENT OF BLEEDING RISK IN PATIENTS WITH HEPATOCELLULAR CARCINOMA RECEIVING SYSTEMIC THERAPY: A SURVEY OF CLINICAL PRACTICE T. Van Broeckhoven1|9, E. Van Gansewinkel5|10, J. De Bruijne2, F. Eskens3, D. De Groot4, K. Hermans5, N. Mohammad6, F. Van Vilsteren7, C. Verslype8, W. Moris9, M. Roest10, B. De Laat10 , J. De Vos-Geelen5, M. Kramer1|9 | 1Department of Gastroenterology and Hepatology, GROW – Research Institute for Oncology and Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands; 2Department of Gastroenterology & Hepatology, Utrecht University, University Medical Center Utrecht, The Netherlands; 3Department of Medical Oncology, Erasmus Medical Centre, Rotterdam, the Netherlands; 4Department of Medical Oncology, University Medical Centre Groningen, University of Groningen, the Netherlands; 5Department of Internal Medicine, Division of Medical Oncology, GROW – Research Institute for Oncology & Reproduction, Maastricht University Medical Center, Maastricht, The Netherlands; 6Department of Medical Oncology, University Medical Centre Utrecht, Utrecht University, Utrecht, the Netherlands; 7Department of Gastroenterology and Hepatology, University Medical Centre Groningen, Groningen, The Netherlands; 8Digestive Oncology, University Hospitals Leuven, Belgium; 9Department of Gastroenterology and Hepatology, Maastricht University Medical Center, Maastricht, The Netherlands; 10Department of Functional Coagulation, Synapse Research Institute, Maastricht, The Netherlands, on behalf of the Dutch Hepatocellular & Cholangiocarcinoma Group
192PDF: 65 -
PO14 | Searching for safer rescue immunosuppressive therapy protocols in acquired hemophilia A: two case reports G. Quintavalle1, I.M. Tassoni1, B.M. Roccon1, G. Lucchini2, F. Magalini2, M. Zardo2, R. Rossi3, C. Cattabiani3, A. Tagliaferri1, A. Coppola1 | 1SSD Centro HUB Emofilia e MEC; 2UOS Medicina Interna e Reumatologia; 3UO Diagnostica Ematochimica, Azienda Ospedaliero Universitaria, Parma, Italy
477PDF: 0 -
CO33 | Acquired hemophilia A in Liguria, Italy: what six years of data reveal C. Vernarecci1, A. C. Molinari1, P. Ballarino2, M. Caiti2, E. Cenni2, P. Moscatelli2, L. Banov1 | 1IRCCS Istituto Giannina Gaslini, Genova; 2IRCCS Policlinico San Martino, Genova, Italy
517PDF: 0 -
CS02 | Functional and structural impairments of the cerebral microcirculation in a mouse model of hemophilia A G. Venturin1, C. Olgasi2, C. Borsotti1, P.E. Di Simone1, E. Spicuglia1 A. Cucci1, C. Sgromo1, A. Follenzi2,3 | 1Department of Health Science, Università del Piemonte Orientale, Novara; 2Department of Translational Medicine, Università del Piemonte Orientale, Novara; 3Department of Attività Integrate Ricerca Innovazione, Azienda Ospedaliero-Universitaria SS. Antonio e Biagio e C. Arrigo, Alessandria, Italy
648PDF: 0 -
CO52 | The impact of KRAS mutations on the risk of recurrent venous thromboembolism in patients with cancer-associated thrombosis and gastrointestinal neoplasms B. Cosmi1,2, S. Cavara2, M. Soldati2, L. Borgese2, M. Sartori2 | 1Angiology and Blood Coagulation Unit, Department of Medical and Surgical Sciences, University of Bologna; 2Angiology and Blood Coagulation Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Italy
513PDF: 0 -
PO53 | PHASE 3 TRIAL EVALUATING THE EFFICACY AND SAFETY OF REGN7508CAT FOR PRIMARY PROPHYLAXIS OF CANCER-ASSOCIATED THROMBOSIS FOR PARTICIPANTS WITH SOLID TUMORS UNDERGOING CANCER TREATMENT (ROXI-CAT-I) J. Zwicker1, M. P. O’Brien2, M. Carrier3, J. Connors4, A. Falanga5, A. Manzano6, R. Mcbane7, Y.Y. Janjigian1, G. O’Kane8, M. Onisko2, J. Kaplan2, A.P. Kithcart2, D.E. Gutstein2, A. Khorana9, M. F. Walsh2 | 1Memorial Sloan Kettering Cancer Center, New York, USA; 2Regeneron Pharmaceuticals, Inc. , Tarrytown, NY, USA; 3University of Ottawa, Ottawa, ON, Canada; 4Harvard Medical School, Boston, MA, USA; 5Hospital Papa Giovanni XXIII, Bergamo, Italy; 6Hospital Universitario 12 de Octubre, Madrid, Spain; 7Mayo Clinic, Rochester, MN, USA; 8St. Vincent's University Hospital and School of Medicine, University College Dublin, Dublin, Ireland; 9James P. Wilmot Cancer Center and the Department of Medicine, University of Rochester, Rochester, NY, USA
207PDF: 78 -
PO12 | Characterisation and real word clinical data of HEM006, a newly formulated intranasal spray desmopressin (DDAVP) to address a global treatment gap G. De Giorgi1, A. Gringeri2, R. Franceschini1, A. Koganti3 | 1Hemorare Srl, Italy; 2Fondazione Charta, Milan, Italy; 3Quenya LLC, USA
481PDF: 0 -
PO02 | SYNERGISTIC INTERACTION OF ENDOTHELIAL AND CANCER CELLS IN THE FORMATION AND STRUCTURE OF THE FIBRIN CLOT SHIELDS M.A. Baghdadi1|2, E. Mbemba1, P. Las Casa1, P. Van Dreden1|3, N. Saleem1|4, J. Fareed4, P. Kempaiah4, M. Sabbah1, G. Gerotziafas1|4 | 1Sorbonne University, INSERM UMR_S_938, CRSA, Research Department "Cancer, Vessels, Biology and Therapeutics" (CaVITE), Research Group "Cancer-Angiogenesis-Thrombosis and Haemostasis," Thrombosis Center, University Institute of Cancerology (UIC), Saint Antoine University Hospital Assistance Publique Hôpitaux de Paris (AP-HP) Paris France; 2Research Center, King Faisal Specialist Hospital and Research Center, Jeddah, Saudi Arabia; 3Diagnostica Stago, clinical research, Gennevilliers, France; 4Center of Translational Research and Education, Department of Pathology and Laboratory Medicine, Loyola University Stritch School of Medicine, Maywood, Ill., USA
219PDF: 43 -
CO32 | Major surgery in patients with severe hemophilia A without inhibitors receiving prophylaxis with fitusiran E. Zanon, C. Simion, A. Napolitano, L. Spiezia, P. Simioni | Haemophilia Center, First Chair of Internal Medicine, Department of Medicine, University-Hospital of Padua Medical School, Padua, Italy
471PDF: 0 -
PO19 | THE INTER-RELATIONSHIP BETWEEN NETOSIS, THE ADAMTS-13/VWF AXIS, AND HEMOSTATIC ACTIVATION IN PATIENTS WITH GYNECOLOGICAL MALIGNANCIES: PROGNOSTIC SIGNIFICANCE AND IMPACT OF CHEMOTHERAPY A. Makatsariya1, E. Beloborodova2,V. Bitsadze1, J. Khizroeva1, A. Vorobev1, A. Solopova1, M. Tretyakova1, N. Gashimova1, K. Grigoreva1, A. Oskolkova1, J. Christophe Gris1|3, I. Elalamy1|4|5, G. Gerotziafas1|4|5 | 1Department of Obstetrics, Gynecology and Perinatal Medicine, N. F. Filatov Clinical Institute of Children’s Health, I. M. Sechenov First Moscow State Medical University Sechenov University, Moscow, Russia; 2MEDSI Network of Medical Centers, Moscow, Russia; 3Faculty of Pharmaceutical and Biological Sciences, Montpellier University, France; 4Department Hematology and Thrombosis Center, Medicine Sorbonne University, Paris, France; 5Hospital Tenon, Paris, France
210PDF: 58 -
PO68 | Whole blood hypercoagulable profiles in a patient with markedly elevated lipoprotein(A) plasma levels and thrombotic complications: a case report C. Portinari, M. Biolo, A. Napolitano, L. Spiezia, A. Colpo, S. Zambon, A. Zambon, P. Simioni | Department of Medicine, Padova University Hospital, Padova, Italy
557PDF: 0
